Whitnell & Co’s Core Laboratories CLB Stock Holding History

Whitnell & Co’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-109	Closed	-$17K	–	278
2013 Q2	$17K	Buy	+109	New	+$15.4K	0.01%	240

Other funds holding CLB

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

VAM

Vontobel Asset Management New York $18.1B AUM 28.09% 1-Year Est. Return

WHV Investments San Francisco, California $187M AUM 14.29% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Whitnell & Co's CLB Position: Q3 2013 in Review

Whitnell & Co sold out of Core Laboratories (CLB) in Q3 2013, closing a stake of 109 shares — an estimated $17K sold.

Whitnell & Co first reported a position in CLB in Q2 2013 and held it in 1 quarter. The position peaked at $17K in Q2 2013. 302 funds tracked by Wall St. Rank hold CLB as of Q3 2013.

Whitnell & Co reported no remaining Core Laboratories position as of Q3 2013 after selling out during the quarter.
Whitnell & Co sold 109 Core Laboratories shares in Q3 2013, an estimated $17K.
Whitnell & Co first reported a position in Core Laboratories in Q2 2013 and held it in 1 quarter.
Whitnell & Co's Core Laboratories position peaked at $17K in Q2 2013.
302 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2013.

Based on Whitnell & Co's 13F filing for Q3 2013, filed 12 Nov 2013.